SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
S*Bio's Oral Histone Deacetylase (HDAC) Inhibitor SB939 Shows Tolerability and Safety in Phase 1 Clinical Trial in Patients with Advanced Hematologic Malignancies